

# Harnessing AI to annotate the severity of all phenotypic abnormalities within the Human Phenotype Ontology

Kitty B Murphy<sup>1,2</sup>, Brian M Schilder<sup>1,2</sup>, Nathan G Skene<sup>1,2</sup>

<sup>1</sup>Department of Brain Sciences, Imperial College London, UK,

<sup>2</sup>UK Dementia Research Institute at Imperial College London, UK,

## 0.1 Abstract

The Human Phenotype Ontology (HPO) has played a crucial role in defining, diagnosing, prognosing, and treating human diseases by providing a standardised framework for describing phenotypic abnormalities. However, documentation on the severity of each phenotype is currently very sparse, making systematic analyses and prioritisation of results challenging. With >17500 phenotypic abnormalities across >8600 rare diseases, manual curation of such phenotypic annotations by experts would be exceedingly labour-intensive and time-consuming. Leveraging advances in artificial intelligence, we employed the OpenAI GPT-4 large language model (LLM) to systematically annotate the severity of all phenotypic abnormalities in the HPO. First, we benchmarked the generative LLM annotations against ground-truth labels within the HPO (e.g. phenotypes in the ‘Cancer’ HPO branch were annotated as causing cancer by GPT-4). True positive recall rates across different annotations ranged from 89-100% (mean=96%), clearly demonstrating the ability of GPT-4 to automate the curation process with a high degree of fidelity. Using a novel approach, we developed a severity scoring system that incorporates both the nature of the phenotype outcome and the frequency of its occurrence. These severity metrics will enable efforts to systematically prioritise which human phenotypes are most detrimental to human health, and best targets for therapeutic intervention.

## 0.2 Introduction

Comprehensive annotation of phenotypic abnormalities is invaluable for defining, diagnosing, prognosing, and treating human disease. Since 2008, the Human Phenotype Ontology (HPO) has been instrumental to this, by providing a standardised database for the description and analysis of human phenotypes (Gargano et al., 2024; Köhler et al., 2021). Through developing open community resources, the depth and breadth of the HPO has continued to expand and there are now >17500 phenotypic abnormalities across >8600 diseases, described. In recent years, the HPO has expanded its disease annotations so that each HPO term can have metadata including typical age of onset and frequency. In addition, there are the *Clinical modifier* and *Clinical course* subontologies, which contains terms to describe factors including severity, triggers, mortality and progression, respectively. Describing the severity-related attributes of a disease is crucial for both research and clinical care of individuals with rare diseases. This includes enhancing diagnostic capabilities, as well as prioritising and guiding gene therapy trials.

To date, the HPO has largely relied on manual curation by experts including clinicians, clinical geneticists and researchers. Although this approach ensures the quality and accuracy of the ontology, it is time-consuming and labour-intensive. As a result, less than 1% of terms within the HPO have metadata pertaining to their features such as time course and severity. Artificial intelligence (AI) capabilities

---

Corresponding author: Kitty B Murphy, [kitty.murphy@ukdri.ac.uk](mailto:kitty.murphy@ukdri.ac.uk)

Corresponding author: Nathan G Skene, [n.skene@imperial.ac.uk](mailto:n.skene@imperial.ac.uk)

have advanced considerably in recent years, presenting new opportunities to integrate natural language processing technologies into assisting in the curation process. Specifically, there have recently been considerable advances in large language model (LLM) and their application to biomedical problems, in some cases performing as well or better than human clinicians on standardised medical exams and patient diagnosis tasks (Bolton et al., n.d.; Cheng et al., 2023; Gu et al., 2021; Labrak et al., n.d.; Luo et al., 2022; McDuff et al., n.d.; O’Neil et al., n.d.; Shin et al., 2020; Singhal et al., n.d., 2023, 2023; Van Veen et al., 2024; Zhang et al., n.d.). Recent work has demonstrated that the Generative Pre-trained Transformer 4 (GPT-4) foundation model (OpenAI et al., n.d.), when combined with strategic prompt engineering, can outperform even specialist LLMs that are explicitly fine-tuned for biomedical tasks (Nori et al., n.d.). In a landmark achievement, GPT-4 was the first LLM to surpass a score of 90% in the United States Medical Licensing Examination (USML) (Nori et al., n.d.).

Here, we have used GPT-4 to systematically annotate the severity of 17502 / 17548 (99.7%) phenotypic abnormalities within the HPO. Our severity annotation framework was adapted from previously defined criteria developed through consultation with clinicians (Lazarin et al., 2014). The authors consulted 192 healthcare professionals for their opinions on the relative severity of various clinical characteristics: they used this to create a system for categorising the severity of diseases. Briefly, each healthcare professional was sent a survey asking them to first rate how important a disease characteristic was for determining disease severity, and then to rate the severity of a set of given disease. Using the responses, the authors were able to categorise clinical characteristics into 4 ‘severity tiers’. While characteristics such as shortened lifespan in infancy and intellectual disability were identified as highly severe and placed into tier 1, sensory impairment and reduced lifespan were categorised as less severe and placed into tier 4. Standardised metrics of severity allow clinicians to quickly assess the urgency of treating a given phenotype, as well as prognosing what outcomes might be expected.

793 phenotypes were annotated multiple times to evaluate the consistency of responses generated by GPT-4. For a subset of phenotypes with known expected annotations, true positive rates were calculated to assess recall. Additionally, based on the clinical characteristics and their occurrence, we have quantified the severity of each phenotype, providing an example of how these clinical characteristic annotations can be used to guide prioritisation of gene therapy trials. Ultimately, we hope that our resource will be of utility to those working in rare diseases, as well as the wider healthcare community.

### 0.3 Results

#### 0.3.1 Annotating the HPO using GPT-4




Figure 1: GPT-4 was able to annotate all human phenotypes based on whether they are always/often/rarely/never associated with different clinical characteristics. **a**, An example of the prompt input given to GPT-4. The phenotypes listed in the second to last sentence (*italicised*) were changed to allow all HPO phenotypes to be annotated. **b**, Stacked bar plot showing the proportion of the occurrence of each clinical characteristic across all annotated HPO phenotypes. The terms shown on the x-axis are the clinical characteristics for which GPT-4 was asked to determine whether each phenotype caused them.

We employed the OpenAI GPT-4 model with Python to annotate 17502 terms within the HPO (v2024-02-08) (Gargano et al., 2024; Köhler et al., 2021). Our annotation framework was developed based on previously defined criteria for classifying disease severity (Lazarin et al., 2014). We sought to evaluate the impact of phenotypes on factors including intellectual disability, death, impaired mobility, physical malformations, blindness, sensory impairments, immunodeficiency, cancer, reduced fertility, and congenital onset. Through prompt design we found that the performance of GPT-4 improved when we incorporated a scale associated with each effect and required a justification for each response. For each effect, we asked about the likelihood of its occurrence - whether it never, rarely, often, or always occurred.

Phenotype outcome occurrence varied across annotation categories. >50% of phenotypes never caused blindness, sensory impairments, immunodeficiency, cancer, reduced fertility or intellectual disability. Only a minority of phenotypes (21.7%)

never had a congenital onset, which is expected as rare disorders tend to be early onset genetic conditions Fig. 1.

Less than 1% of phenotype always directly resulted in death, such as ‘Stillbirth’, ‘Anencephaly’ and ‘Bilateral lung agenesis’. Only 71 phenotypes were annotated as always causing death, while 9707 phenotypes were annotated as often or rarely causing death. 7880 phenotypes were annotated as never causing death. This included 34 unique forms of syndactyly, a non-lethal condition that causes fused or webbed fingers (occurring 1 in 1,200–15,000 live births). While not life-threatening itself, syndactyly is a symptom of genetic disorders that can cause life-threatening cardiovascular and neurodevelopmental defects, such as Apert Syndrome (Garagnani & Smith, 2013). This example highlights the ability of GPT-4 to successfully distinguish between phenotypes that directly cause lethality, and those that are often associated with diseases that cause lethality.

### 0.3.2 Annotation consistency and recall

To assess annotation consistency, 793 phenotypes underwent duplicate annotations. We employed two different metrics to determine the *consistency rate*. The first, less stringent metric, defined consistency as the duplicate annotations being either ‘always’ and ‘often’, or ‘never’ and ‘rarely’. The second, more stringent metric, required exact agreement in annotation occurrences, e.g. ‘always’ and ‘always’. For the less stringent metric, duplicated phenotypes were annotated consistently at a rate of at least 80%, and for the more stringent metric, the lowest consistency rate was 57% for congenital onset. An example of where annotations were inconsistent was for the HPO term ‘Acute leukaemia’. One time, GPT-4 annotated it as often causing impaired mobility, giving the justification that ‘weakness and fatigue from leukaemia and its treatment can impair mobility’. The other time, GPT-4 annotated it as rarely causing impaired mobility, giving the justification that ‘acute leukaemia rarely impairs mobility directly’. Despite specifying in the prompt for GPT-4 not to take into consideration indirect effects, here is an example of where it failed to do so.




Figure 2: GPT-4 annotations are consistent and accurate across annotations. **a**, Barplot showing the annotation consistency within phenotypes that were annotated more than once. In the lenient metric, annotations were collapsed into two groups ('always'/'often' and 'never'/'rarely'). For a given clinical characteristic within a given phenotype, if an annotation was always within the same group it was considered consistent. In the stringent metric, all four annotation categories were considered to be different from one another. Thus, annotations were only defined as consistent if they were all identical. The blue dashed line indicates the probability of two annotations being consistent by chance in the lenient metric ( $\sim 1/2$ ). The gold dashed line is the probability of two annotations being consistent by chance in the stringent metric ( $\sim 1/4$ ). **b**, Bar plot of the true positive rate for each annotation. The labels above each bar indicate the number of phenotypes tested.

In order to evaluate the validity of the annotations, we calculated a true positive rate. This involved identifying specific branches within the HPO that would contain phenotypes that would reliably indicate the presence of certain conditions. For instance, the phenotypes 'Decreased fertility in females' and 'Decreased fertility in males' should often or always cause reduced fertility. We observed an encouraging true positive rate exceeding 88% across in every clinical characteristic and achieving perfect recall (100%) in 4/8 characteristics.

The lowest true positive rate was observed for physical malformations, with 88.5% recall across 87 HPO phenotypes. Some cases in which the GPT-4 annotations disagreed with the HPO ground truth included: 'Angioma serpentinum', 'Nevus anemicus', 'Pulmonary arteriovenous fistulas'. In the case of 'Angioma serpentinum' it provided the justification that 'No known association with physical malformations'. In another instance, GPT-4 noted that 'Nevus anemicus' is 'Limited to hypopig-

mented skin patch; no other malformations.’. This indicates that while technically incorrect according to our predefined benchmarks, a case could in fact be made that mild skin conditions do not rise to the level of physical malformations.

This high level of recall underscores the robustness of our annotations and the reliability of the HPO framework in capturing clinically relevant phenotypic information. However, we acknowledge that the number of testable true positive phenotypes for some of these categories are low, especially ‘blindness’ for which there is only 1 phenotype in the HPO (after excluding terms pertaining to colour or night blindness). Furthermore, some of the true positive phenotypes are lexically similar to the name of the clinical characteristic itself. In these cases, annotating ‘Severe intellectual disability’ as always causing intellectual disability is a relatively trivial task. Nevertheless, even these scenarios provide a clear and interpretable benchmark for the model’s performance. In addition, were numerous phenotypes with lexically non-obvious relationships to the clinical characteristic that were annotated correctly by GPT-4. For example, ‘Molar tooth sign on MRI’ was correctly annotated as causing intellectual disability.

### ***0.3.3 Quantifying phenotypic severity***

Quantifying the severity of phenotypes can have important implications for diagnosis, prognosis, and treatment, for instance, guiding prioritisation of gene therapy trials for the most severe phenotypes. First, we created a dictionary to map each phenotype outcome (e.g. blindness) and its response (always, often, rarely, never) to numeric values from 0-3. Then, the phenotype outcome values were multiplied by their associated response values. Importantly, the values reflected the severity of each outcome based on both the outcome itself and the frequency of the response. For instance, a phenotype always causing death would have a higher multiplied value than a phenotype rarely causing reduced fertility (see Table 2). Next, we computed an average score for each phenotype by aggregating the multiplied values across all phenotype outcomes and then calculating the mean. This was then normalised by the theoretical maximum severity score, so that all phenotypes were on a 0-100 severity scale (where 100 is the most severe phenotype possible). This average normalised score represents the overall severity of the phenotype based on the severity of its individual outcomes.

Based on these scores we evaluated the top 50 severe phenotypes. One of the most severe phenotype was ‘Anencephaly’ (HP:0002323) with a composite severity score of 52. Anencephaly is a birth defect where the baby is born without a portion of its brain and skull, often these babies are stillborn. In fact, many of the most severe phenotypes were related to developmental brain and neural tube defects. Comparison of the severity scores for each response, across the phenotype outcomes annotated, revealed consistent trends: as the response of the phenotype outcome increased (from never to always), the severity score also increased (Supplementary Fig. 5). We also evaluated the severity score distribution by HPO branch and calculated the mean severity score using all phenotypes within each major HPO branch (Fig. 4). The HPO branch with the greatest mean severity score was ‘Abnormal cellular phenotype’ (mean=19.6), followed by ‘Neoplasm’ (mean=17.2), which would include the highly ranked phenotypes seen in Figure 3.




Figure 3: Quantifying the severity of HPO phenotype annotations highlights the most impactful conditions. Heatmap of the top ( $n = 15$ ), mid-range ( $n = 15$ ), and bottom ( $n = 15$ ) HPO phenotypes based on severity score. Severity scores were calculated by multiplying the numeric values assigned to each clinical characteristic according to Table 2. The average normalised score, representing overall phenotype severity on a 0-100 scale, was calculated by aggregating the multiplied values and normalising by the theoretical maximum severity score. The x-axis is scaled by the severity of the clinical characterisation.

#### 0.4 Discussion

The creation and annotation of biomedical knowledge has traditionally relied on manual or semi-manual curation by human experts (Gargano et al., 2024; Köhler et al., 2021; Mungall et al., 2017; Ochoa et al., 2021; Putman et al., 2024). Performing such manual curation and review tasks at scale is often infeasible for human biomedical experts given limited time and resources. LLMs have the capacity to effectively encode, retrieve, and synthesise vast amounts of diverse information in a highly scalable manner (OpenAI et al., n.d.; Singhal et al., 2023; Van Veen et al., 2024). This makes them powerful tools that can be applied in a rapidly expanding variety of scenarios, including medical practice, research and data curation (Caufield et al., n.d.; O’Neil et al., n.d.; Pan et al., n.d.; Singhal et al., 2023; Toro et al., n.d.).

Here, we introduce a novel framework to leverage the current best-in-class LLM, GPT-4 (OpenAI et al., n.d.), to systematically annotate the severity of 17502 phe-



notypic abnormalities within the HPO. By employing advanced AI capabilities, we have demonstrated the feasibility of automating this process, significantly enhancing efficiency without substantially compromising accuracy. Our validation approach yielded a high true positive rate exceeding 88% across the phenotypes tested. Furthermore, our approach can be readily adapted and scaled to accommodate the growing volume of phenotypic data.

Throughout this study, we observed that GPT-4 was capable of reliably recovering deep semantic relationships from the medical domain, far beyond making superficial inferences based on lexical similarities. An excellent example of this is the phenotype ‘Molar tooth sign on MRI’ (HP:0002419; severity score=30), which GPT-4 annotated as causing intellectual disability. At first glance, we ourselves assumed this was a false positive as the term appeared to be related to dentition. However, upon further inspection we realised that molar tooth sign is in fact a pattern of abnormal brain morphology that happens to bear some resemblance to molar dentition when observed in radiological scans. This phenotype is a known sign of neurodevelopmental defects that can indeed cause severe intellectual disability (Gleeson et al., 2004).

In addition to rapidly synthesising and summarising vast amounts of information, LLMs can also be steered to provide justifications for each particular response. This makes LLMs amenable to direct interrogation as a means of recovering explainability, especially when designed to retain information about previous requests and interactions as they use these to iteratively improve and update their predictions (Janik, n.d.). This represents a categorical advance over traditional natural language processing models based on more shallow forms of statistical or machine learning (e.g. Term Frequency-Inverse Document Frequency (Jones, 1972), Word2vec (Mikolov et al., n.d.)) which lack the ability to provide chains of causal reasoning to justify their predictions. This highlights the fundamental trade-off between simpler models with high explainability (the ability humans to understand the inner workings of the model) but low interpretability (the ability of humans to trace the decision process of the model, analogous to human ‘reasoning’), and deeper more complex models with low explainability but high interpretability (Marcinkevičs & Vogt, n.d.).

A key contribution of our study is the introduction of a quantitative severity scoring system that integrates both the nature of the phenotype outcome and the frequency of its occurrence. By encoding the concept of severity in this way, we are able to prioritise phenotypes based on their impact on patients. The methodology allowed us to transition from low-throughput qualitative assessments of severity (e.g. Lazarin et al. (2014)) to high-throughput quantitative assessments of severity. One of the most severe phenotypes in the HPO is ‘Fetal akinesia sequence’ (FAS; HP:0001989, severity score= 50.7), and extremely rare condition that is almost always lethal. FAS is a complex, multi-system phenotype that can be caused by at least 24 different genetic disorders. Despite the complex and heterogenous aetiology of this phenotype, GPT-4 was able to provide accurate annotations alongside explainable justifications for those annotations (see Table 3). For example, this phenotype almost always results in death, either *in utero* or shortly after birth. Not only did GPT-4 correctly provide the annotation death as ‘always’, when asked whether FAS causes sensory impairments it provided the response ‘always’ with the justification ‘Fetal akinesia sequence typically results in severe sensory impairment due to neurodevelopmental disruption.’ Neurodevelopmental disruption is indeed a hallmark component of FAS (e.g. hydrocephalus, cerebellar hypoplasia) that causes severe impairments across multiple sensory systems (Chen, 2012). This demonstrates that GPT-4 was able to recover the correct chain of causality from phenotype to clinical outcome.

Our findings highlight the potential of this next generation of natural language processing technologies in significantly contributing to the automation and refinement



of data curation in biomedical research. These results have a large number of useful real-world applications, such as prioritising gene therapy candidates (Murphy et al., n.d.) and guiding clinical decision-making in rare diseases. As the HPO continues to grow over time, this approach can easily be repeated to keep pace with the rapidly evolving biomedical landscape. Furthermore, this approach can be extended to produce different sets of annotations or be used with any other ontology. Additional use cases include gathering data on the prevalence of each phenotype to approximate their social and financial costs.

One key limitation of our study is the fact that we did not explicitly interrogate GPT-4 to assess how the availability of treatments affected the annotations it produced. For example, there are some very severe conditions for which highly effective treatments and early detection screens are widely available (e.g. syphilis, some forms of melanoma), thus rendering them fully treatable or even curable provided access to modern healthcare. It would therefore be useful to further interrogate GPT-4 to uncover how the availability of treatments influences its responses. Many of our findings here seem to indicate that GPT-4 does take into account quality of care to the extent that health services increase the likelihood of desired outcomes. For example, many of the cancer phenotypes are justified as always or often causing death unless detected and treated early in the disease course. On the other hand, some cancers are justified as rarely causing death if appropriate treatment is provided, which may not always be the case for individuals or populations with access to less access to quality healthcare services. Future efforts could more explicitly ask GPT-4 whether the phenotype would cause death with no or suboptimal treatment.

In addition to these technical challenges, there are multiple factors that need to be considered when trying to prioritise phenotypes for their suitability for gene therapy development. First, while we have attempted to formalise severity here, this is an inherently subjective concept that may vary considerably across different individuals and contexts. For instance, one could ask whether a condition that always causes death is worse than a condition that causes a lifetime of severe disability (e.g. paralysis, blindness, intellectual disability). Metrics such as quality-adjusted life years (QALYs) have been proposed in the past to address these dilemmas by defining health as a function of both the length and quality of life (Prieto & Sacristán, 2003). With regards to the financial burden of diseases, in some situations phenotypes which require many years of expensive medical care may be prioritised over those that result in extremely early onset lethality and little opportunity for therapeutic intervention. Another factor that affects the viability of a therapeutic program is the speed, cost and other practical considerations of a clinical trial. For instance, measuring risk of ageing-related respiratory failure over a ten-year period may be impractical in some cases. However, testing for total reversal of an existing severe phenotype could potentially yield faster and more immediately impactful results. If performed in close collaboration with medical ethicists, governmental organisations, advocacy groups and patient families, such cost/benefit assessments could be aided by LLMs through the scalable gathering of relevant data. As AI capabilities continue to advance, the range of applications in which they can be used effectively will continue to grow.

While our study demonstrates the feasibility and utility of AI-driven phenotypic annotation, several limitations must be acknowledged. The reliance on computational algorithms may introduce biases or inaccuracies inherent to the training data, necessitating ongoing validation and refinement of our approach. Additionally, our severity scoring system, while comprehensive, may not capture the full spectrum of phenotypic variability or account for complex gene-environment interactions. Future research should focus on further optimising AI-driven annotation methodologies, incorporating additional data modalities such as genomic and clinical data to enhance accuracy.

In conclusion, our study represents a significant step towards harnessing the power of AI to advance phenotypic annotation and severity assessment across all rare diseases. This resource aims to provide researchers and clinicians with actionable insights that can inform rare disease research and improve the lives of individuals affected by rare diseases.

## 0.5 Methods

### 0.5.1 Annotating the HPO using OpenAI GPT-4

We wrote a Python script to iteratively query GPT-4 via the OpenAI application programming interface (API). The ultimately yielded consistently formatted annotations for 17502 terms within the HPO. Our annotation framework was developed based on previously defined criteria for classifying disease severity (Lazarin et al., 2014). We sought to evaluate whether each phenotype directly caused a given severity-related clinical characteristic, including: intellectual disability, death, impaired mobility, physical malformations, blindness, sensory impairments, immunodeficiency, cancer, reduced fertility, and/or had a congenital onset. Through prompt engineering we found that the performance of GPT-4 improved when we incorporated a scale associated with each effect and required a justification for each response. We asked how frequently the given phenotype directly causes each clinical characteristic - whether it never, rarely, often, or always occurred. Furthermore, our prompt design revealed that the optimal trade-off between the number of phenotypes and performance (in terms of producing the desired annotations, and adhering to the formatting requirements) was achieved when inputting no more than two or three phenotypes per prompt. An example prompt can be seen in Figure 1. Only 2 phenotypes were included per prompt in order to 1) avoid exceeding per-query token limits, and 2) prevent the breakdown of GPT-4 performance due to long-form text input, which is presently a known limitation common to many LLMs including GPT-4 (Wei et al., n.d.).

### 0.5.2 Calculating the true positive rate

Table 1: For each clinical characteristic, any terms that matched

Clinical characteristic	HPO queries	True positive HPO IDs
Intellectual disability	Intellectual disability; Mental deterioration	19
Impaired mobility	Gait disturbance; Diminished movement; mobility	319
Physical malformations	malformation	78
Blindness	blindness	1
Sensory impairments	Abnormality of vision; Abnormality of the sense of smell; Abnormality of taste sensation; Somatic sensory dysfunction; Hearing abnormality	252
Immunodeficiency	Immunodeficiency; Impaired antigen-specific response	29
Cancer	Cancer; malignant; carcinoma	56
Reduced fertility	Decreased fertility; Hypogonadism	9

A true positive rate was calculated as a measure of the recall of the GPT-4 annotations. This was achieved by identifying specific branches within the HPO that would contain phenotypes that would reliably indicate the occurrence of certain clin-

ical characteristics, and using all descendants of this HPO branch as true positives. For example, all descendants of the terms ‘Intellectual disability’ (HP:0001249) or ‘Mental deterioration’ (HP:0001268) should be annotated as always or often causing intellectual disability (Table 1).

### 0.5.3 Quantifying phenotypic severity

The GPT-4 generated annotation occurrences were converted into a semi-quantitative scoring system, with ‘always’ corresponding to 3, ‘often’ to 2, ‘rarely’ to 1, and ‘never’ to 0. These scores were then weighted by a severity metric on a scale of 1-5, with 5 representing the highest severity, as determined by the provided annotations (Table 2). Subsequently, the weighted scores underwent normalisation to yield a final quantitative severity score ranging from 0-100, with 100 signifying the maximum severity score attainable.

Let us denote:

- $p$  : a phenotype in the HPO.
- $j$  : the identity of a given annotation metric (i.e. clinical characteristic, such as ‘intellectual disability’ or ‘congenital onset’).
- $W_j$ : the assigned weight of metric  $j$ .
- $F_j$ : the maximum possible value for metric  $j$  (equivalent across all  $j$ ).
- $F_{pj}$  : the numerically encoded value of annotation metric  $j$  for phenotype  $p$ .
- $NSS_p$ : The final composite severity score for phenotype  $p$  after applying normalisation to align values to a 0-100 scale and ensure equivalent meaning regardless of which other phenotypes are being analysed in addition to  $p$ . This allows for direct comparability of severity scores across studies with different sets of phenotypes.

$$NSS_p = \frac{\sum_{j=1}^m (F_{pj} \times W_j)}{\sum_{j=1}^m (\max\{F_j\} \times W_j)} \times 100$$

Diagram illustrating the formula for Normalised Severity Score ( $NSS_p$ ):

- Sum of weighted annotation values across all metrics** (Numerator):  $\sum_{j=1}^m (F_{pj} \times W_j)$
- Theoretical maximum severity score** (Denominator):  $\sum_{j=1}^m (\max\{F_j\} \times W_j)$
- Numerically encoded annotation value of metric  $j$  for phenotype  $p$** :  $F_{pj}$
- Weight for metric  $j$** :  $W_j$
- Normalised Severity Score for each phenotype**:  $NSS_p$

Table 2: Weighted scores for each clinical characteristic and GPT-4 response category.

Clinical characteristic	Always (3)	Often (2)	Rarely (1)	Never (0)
Intellectual disability (5)	15	10	5	0
Death (5)	15	10	5	0
Impaired mobility (4)	12	8	4	0
Blindness (4)	12	8	4	0
Physical malformations (3)	9	6	3	0
Sensory impairments (3)	9	6	3	0
Immunodeficiency (3)	9	6	3	0
Cancer (3)	9	6	3	0
Reduced fertility (1)	3	2	1	0
Congenital onset (1)	3	2	1	0

## 0.6 Data and code availability statement

All code and data used in this study are available on GitHub at:

[https://github.com/neurogenomics/gpt\\_hpo\\_annotations](https://github.com/neurogenomics/gpt_hpo_annotations)

The GPT-4 annotations for all HPO phenotypes are made available through the R function `HPOExplorer::gpt_annot_read` or in CSV format at:

[https://github.com/neurogenomics/gpt\\_hpo\\_annotations/tree/master/data](https://github.com/neurogenomics/gpt_hpo_annotations/tree/master/data)

A fully reproducible version of this Quarto manuscript can be found at:

[https://github.com/neurogenomics/gpt\\_hpo\\_annotations/blob/master/manuscript.qmd](https://github.com/neurogenomics/gpt_hpo_annotations/blob/master/manuscript.qmd)

## 0.7 Acknowledgements

We would like to thank members of the Monarch Initiative for their insight and feedback throughout this project. In particular, Peter Robinson.

### 0.7.1 Funding

This work was supported by a UK Dementia Research Institute (UK DRI) Future Leaders Fellowship [MR/T04327X/1] and the UK DRI which receives its funding from UK DRI Ltd, funded by the UK Medical Research Council, Alzheimer's Society and Alzheimer's Research UK.

## References

- Bolton, E., Venigalla, A., Yasunaga, M., Hall, D., Xiong, B., Lee, T., et al. (n.d.). BioMedLM: A 2.7B parameter language model trained on biomedical text. <https://doi.org/10.48550/arXiv.2403.18421>
- Caufield, J. H., Hegde, H., Emonet, V., Harris, N. L., Joachimiak, M. P., Matentzoglou, N., et al. (n.d.). Structured prompt interrogation and recursive extraction of semantics (SPIRES): A method for populating knowledge bases using zero-shot learning. <https://doi.org/10.48550/arXiv.2304.02711>
- Chen, C.-P. (2012). Prenatal diagnosis and genetic analysis of fetal akinesia deformation sequence and multiple pterygium syndrome associated with neuromuscular junction disorders: A review. *Taiwanese Journal of Obstetrics and Gynecology*, 51(1), 12–17. <https://doi.org/10.1016/j.tjog.2012.01.004>
- Cheng, K., Guo, Q., He, Y., Lu, Y., Gu, S., & Wu, H. (2023). Exploring the potential of GPT-4 in biomedical engineering: The dawn of a new era. *Annals of Biomedical Engineering*, 51(8), 1645–1653. <https://doi.org/10.1007/s10439-023-03221-1>
- Garagnani, L., & Smith, G. D. (2013). Syndromes associated with syndactyly. In J. M. Abzug, S. Kozin, & D. A. Zlotolow (Eds.), *The pediatric upper extremity* (pp. 1–31). Springer. [https://doi.org/10.1007/978-1-4614-8758-6\\_14-1](https://doi.org/10.1007/978-1-4614-8758-6_14-1)
- Gargano, M. A., Matentzoglou, N., Coleman, B., Addo-Lartey, E. B., Anagnostopoulos, A. V., Anderton, J., et al. (2024). The human phenotype ontology in 2024: Phenotypes around the world. *Nucleic Acids Research*, 52(D1), D1333–D1346. <https://doi.org/10.1093/nar/gkad1005>
- Gleeson, J. G., Keeler, L. C., Parisi, M. A., Marsh, S. E., Chance, P. F., Glass, I. A., et al. (2004). Molar tooth sign of the midbrain–hindbrain junction: Occurrence in multiple distinct syndromes. *American Journal of Medical Genetics Part A*, 125A(2), 125–134. <https://doi.org/10.1002/ajmg.a.20437>
- Gu, Y., Tinn, R., Cheng, H., Lucas, M., Usuyama, N., Liu, X., et al. (2021). Domain-specific language model pretraining for biomedical natural language processing. *ACM Transactions on Computing for Healthcare*, 3(1), 2:1–2:23. <https://doi.org/10.1145/3458754>
- Janik, R. A. (n.d.). Aspects of human memory and large language models. <https://doi.org/10.48550/arXiv.2311.03839>

- Jones, K. S. (1972). A statistical interpretation of term specificity and its application in retrieval. *Journal of Documentation*, 28(1), 11–21. <https://doi.org/10.1108/eb026526>
- Köhler, S., Gargano, M., Matentzoglou, N., Carmody, L. C., Lewis-Smith, D., Vasilevsky, N. A., et al. (2021). The human phenotype ontology in 2021. *Nucleic Acids Research*, 49(D1), D1207–D1217. <https://doi.org/10.1093/nar/gkaa1043>
- Labrak, Y., Bazoge, A., Morin, E., Gourraud, P.-A., Rouvier, M., & Dufour, R. (n.d.). BioMistral: A collection of open-source pretrained large language models for medical domains. <https://doi.org/10.48550/arXiv.2402.10373>
- Lazarin, G. A., Hawthorne, F., Collins, N. S., Platt, E. A., Evans, E. A., & Haque, I. S. (2014). Systematic classification of disease severity for evaluation of expanded carrier screening panels. *PLoS One*, 9(12), e114391.
- Luo, R., Sun, L., Xia, Y., Qin, T., Zhang, S., Poon, H., & Liu, T.-Y. (2022). BioGPT: Generative pre-trained transformer for biomedical text generation and mining. *Briefings in Bioinformatics*, 23(6), bbac409. <https://doi.org/10.1093/bib/bbac409>
- Marcinkevičs, R., & Vogt, J. E. (n.d.). Interpretability and explainability: A machine learning zoo mini-tour. <https://doi.org/10.48550/arXiv.2012.01805>
- McDuff, D., Schaekermann, M., Tu, T., Palepu, A., Wang, A., Garrison, J., et al. (n.d.). Towards accurate differential diagnosis with large language models. <https://doi.org/10.48550/arXiv.2312.00164>
- Mikolov, T., Chen, K., Corrado, G., & Dean, J. (n.d.). Efficient estimation of word representations in vector space. <https://doi.org/10.48550/arXiv.1301.3781>
- Mungall, C. J., McMurtry, J. A., Köhler, S., Balhoff, J. P., Borromeo, C., Brush, M., et al. (2017). The monarch initiative: An integrative data and analytic platform connecting phenotypes to genotypes across species. *Nucleic Acids Research*, 45(D1), D712–D722. <https://doi.org/10.1093/nar/gkw1128>
- Murphy, K. B., Gordon-Smith, R., Chapman, J., Otani, M., Schilder, B. M., & Skene, N. G. (n.d.). Identification of cell type-specific gene targets underlying thousands of rare diseases and subtraits. <https://doi.org/10.1101/2023.02.13.23285820>
- Nori, H., Lee, Y. T., Zhang, S., Carignan, D., Edgar, R., Fusi, N., et al. (n.d.). Can generalist foundation models outcompete special-purpose tuning? Case study in medicine. <https://doi.org/10.48550/arXiv.2311.16452>
- O’Neil, S. T., Schaper, K., Elsarboukh, G., Reese, J. T., Moxon, S. A. T., Harris, N. L., et al. (n.d.). Phenomics assistant: An interface for LLM-based biomedical knowledge graph exploration. <https://doi.org/10.1101/2024.01.31.578275>
- Ochoa, D., Hercules, A., Carmona, M., Suveges, D., Gonzalez-Uriarte, A., Malan-gone, C., et al. (2021). Open targets platform: Supporting systematic drug-target identification and prioritisation. *Nucleic Acids Research*, 49(D1), D1302–D1310. <https://doi.org/10.1093/nar/gkaa1027>
- OpenAI, Achiam, J., Adler, S., Agarwal, S., Ahmad, L., Akkaya, I., et al. (n.d.). GPT-4 technical report. <https://doi.org/10.48550/arXiv.2303.08774>
- Pan, J. Z., Razniewski, S., Kalo, J.-C., Singhanian, S., Chen, J., Dietze, S., et al. (n.d.). Large language models and knowledge graphs: Opportunities and challenges. <https://doi.org/10.48550/arXiv.2308.06374>
- Prieto, L., & Sacristán, J. A. (2003). Problems and solutions in calculating quality-adjusted life years (QALYs). *Health and Quality of Life Outcomes*, 1, 80. <https://doi.org/10.1186/1477-7525-1-80>
- Putman, T. E., Schaper, K., Matentzoglou, N., Rubinetti, V. P., Alquaddoomi, F. S., Cox, C., et al. (2024). The monarch initiative in 2024: An analytic platform integrating phenotypes, genes and diseases across species. *Nucleic Acids Research*, 52(D1), D938–D949. <https://doi.org/10.1093/nar/gkad1082>
- Shin, H.-C., Zhang, Y., Bakhturina, E., Puri, R., Patwary, M., Shoeybi, M., & Mani, R. (2020). BioMegatron: Larger biomedical domain language model. In B. Web-

- ber, T. Cohn, Y. He, & Y. Liu (Eds.), *Proceedings of the 2020 conference on empirical methods in natural language processing (EMNLP)* (pp. 4700–4706). Association for Computational Linguistics. <https://doi.org/10.18653/v1/2020.emnlp-main.379>
- Singhal, K., Tu, T., Gottweis, J., Sayres, R., Wulczyn, E., Hou, L., et al. (n.d.). Towards expert-level medical question answering with large language models. <https://doi.org/10.48550/arXiv.2305.09617>
- Singhal, K., Azizi, S., Tu, T., Mahdavi, S. S., Wei, J., Chung, H. W., et al. (2023). Large language models encode clinical knowledge. *Nature*, 1–9. <https://doi.org/10.1038/s41586-023-06291-2>
- Toro, S., Anagnostopoulos, A. V., Bello, S., Blumberg, K., Cameron, R., Carmody, L., et al. (n.d.). Dynamic retrieval augmented generation of ontologies using artificial intelligence (DRAGON-AI). <https://doi.org/10.48550/arXiv.2312.10904>
- Van Veen, D., Van Uden, C., Blankemeier, L., Delbrouck, J.-B., Aali, A., Bluethgen, C., et al. (2024). Adapted large language models can outperform medical experts in clinical text summarization. *Nature Medicine*, 1–9. <https://doi.org/10.1038/s41591-024-02855-5>
- Wei, J., Yang, C., Song, X., Lu, Y., Hu, N., Huang, J., et al. (n.d.). Long-form factuality in large language models. Retrieved from <http://arxiv.org/abs/2403.18802>
- Zhang, K., Yu, J., Yan, Z., Liu, Y., Adhikarla, E., Fu, S., et al. (n.d.). BiomedGPT: A unified and generalist biomedical generative pre-trained transformer for vision, language, and multimodal tasks. <https://doi.org/10.48550/arXiv.2305.17100>

495

**0.8 Supplementary Materials**

496


**0.8.1 Supplementary Figures**

Figure 4: Distribution of the composite GPT-4 severity score of the severity scores for all HPO terms.






Figure 5: Boxplot showing the relationship between composite severity score (y-axis) and the frequency response categories within each annotation type.

**0.8.2 Supplementary Tables**

Table 3: Severity notations generated for GPT-4 annotations for the HPO phenotype ‘Fetal akinesia sequence’ (HP:000198).

Clinical characteristic	Annotation	Justification
Intellectual disability	always	Fetal akinesia sequence typically results in severe neurodevelopmental impairment, including intellectual disability.
Death	always	Fetal akinesia sequence is typically fatal in utero or shortly after birth.
Impaired mobility	always	Fetal akinesia sequence results in severe physical impairment, including impaired mobility.
Physical malformations	always	Fetal akinesia sequence is associated with multiple physical malformations.
Blindness	often	Visual impairment is common in surviving individuals with fetal akinesia sequence due to neurodevelopmental impairment.
Sensory impairments	always	Fetal akinesia sequence typically results in severe sensory impairment due to neurodevelopmental disruption.
Immunodeficiency	may	While not a direct feature, some individuals with fetal akinesia sequence may have associated immune abnormalities.
Cancer	never	Fetal akinesia sequence does not cause cancer.
Reduced fertility	often	Given the severe physical impairments associated with fetal akinesia sequence, fertility is likely to be reduced in surviving individuals.
Congenital onset	always	Fetal akinesia sequence is a congenital disorder.